Related Experiment Videos
Silent myocardial ischemia
1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN.
Insights
Silent ischemia, indicated by ST-segment depression without symptoms, is a significant marker for coronary artery disease. Reducing this silent ischemia may improve patient outcomes, though further proof is needed.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- ST-segment depression without symptoms is a recognized abnormality in coronary artery disease patients.
- This silent ischemia signifies myocardial perfusion defects and is a key indicator of cardiac events.
Purpose of the Study:
- To highlight the prognostic importance of silent ischemia in coronary artery disease.
- To discuss the concept of total ischemic burden and its potential modification.
Main Methods:
- Utilized 24-hour ambulatory ECG monitoring to detect episodes of ST-segment depression.
- Analyzed the occurrence of silent ischemia in relation to heart rate and symptoms.
Main Results:
- Most ischemic episodes in coronary artery disease patients are silent, occurring at normal heart rates.
- Silent ischemia, combined with angina-related ischemia, defines total ischemic burden.
Conclusions:
- Silent ischemia is a critical prognostic marker for future myocardial events.
- Standard antianginal therapy can reduce silent ischemia and total ischemic burden, potentially improving patient outcomes.
Abstract:
ST-segment depression in the absence of symptoms is now a well-defined abnormality in patients with coronary artery disease. ST-segment depression without the occurrence of angina is a marker for myocardial perfusion defects and ischemia. During 24-hour recordings, most episodes of ischemia in patients with coronary artery disease are silent and occur with relatively normal heart rates. The combination of silent ischemia and ischemia associated with angina is referred to as total ischemic burden. Silent ischemia is prognostically important for identifying patients in whom subsequent myocardial events may develop. The episodes of silent ischemia, and thus total ischemic burden, can be reduced by standard antianginal therapy, a measure that may have a favorable influence on patient outcome. Proof that reduction of the total ischemic burden actually improves outcome, however, is not yet available.